The clinical presentation of asthma and intensity of airway inflammation presents with heterogeneity. Asthma management aims to minimize the symptoms and risks of exacerbations to achieve control over the disease. Risk factors include smoking, obesity, occupational and environmental risk factors, and a genetic predisposition, among others. Asthma therapy aims to minimize the symptoms and risks of exacerbations to achieve control over the disease. Pharmacological treatment of asthma is based on an assessment and reevaluation cycle where symptoms, risk factors, comorbidities, and side effects are all examined. In this article, we aim to provide a summarized, yet comprehensive paper that discusses Asthma presentation in primary health care, and its diagnostic and management approach. The Medline, Pubmed, Embase, NCBI, and Cochrane databases were searched for studies of patients with asthma symptoms. Incidence, etiology, and management options were analyzed. Asthma is a complex and heterogenic disease originating from a multitude of gene-environment interactions. Most asthma presents type 2 inflammation, seen in allergic conditions. Asthma presents in episodes, with environmental triggers that tend to vary among asthmatics. Treatment does not cure the disease but rather the objective is to maintain control.
1. Wu TD, Brigham EP, McCormack MC. Asthma in the primary care setting. Med Clin. 2019;103(3):435-52.
2. Vos T, Flaxman AD, Naghavi M, Lozano R, Michaud C, Ezzati M. A systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380(9859):2163-96.
3. To T, Stanojevic S, Moores G, Gershon AS, Bateman ED, Cruz AA, et al. Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health. 2012;12(1):1-8.
4. Asher MI, Montefort S, Björkstén B, Lai CK, Strachan DP, Weiland SK, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet. 2006;368(9537):733-43.
5. Cabieses B, Uphoff E, Pinart M, Antó JM, Wright J. A systematic review on the development of asthma and allergic diseases in relation to international immigration: the leading role of the environment confirmed. PLoS One. 2014;9(8):e105347.
6. Leynaert B, Sunyer J, Garcia-Esteban R, Svanes C, Jarvis D, Cerveri I, et al. Gender differences in prevalence, diagnosis and incidence of allergic and non-allergic asthma: a population-based cohort. Thorax. 2012;67(7):625-31.
7. Andersson M, Hedman L, Bjerg A, Forsberg B, Lundbäck B, Rönmark E. Remission and persistence of asthma followed from 7 to 19 years of age. Pediatrics. 2013;132(2):e435-42.
8. Dixon AE. Rhinosinusitis and asthma: the missing link. Curr Opin Pulm Med. 2009;15(1):19-24.
9. Rabe KF, Adachi M, Lai CK, Soriano JB, Vermeire PA, Weiss KB, et al. Worldwide severity and control of asthma in children and adults: the global asthma insights and reality surveys. J Allergy Clin Immunol. 2004;114(1):40-7.
10. Jung KH, Hsu SI, Yan B, Moors K, Chillrud SN, Ross J, et al. Childhood exposure to fine particulate matter and black carbon and the development of new wheeze between ages 5 and 7 in an urban prospective cohort. Environ Int. 2012;45:44-50.
11. Weiss ST. Obesity: insight into the origins of asthma. Nat Immunol. 2005;6(6):537-9.
12. Sutherland ER, Goleva E, Strand M, Beuther DA, Leung DY. Body mass and glucocorticoid response in asthma. Am J Respir Crit Care Med. 2008;178(7):682-7.
13. Ducharme FM, Sze MT, Chauhan B. Diagnosis, management, and prognosis of preschool wheeze. Lancet. 2014;383(9928):1593-604.
14. Shen H, Hua W, Wang P, Li W. A new phenotype of asthma: chest tightness as the sole presenting manifestation. Ann Allergy Asthma Immunol. 2013;111(3):226-7.
15. Kubaeva MB, Ivanov DA, Zyryanov SK. Optimization of clinical and pharmacological approaches to the treatment of patients with bronchial asthma. J Adv Pharm Educ Res. 2020;10(3):111-4.
16. Rosenberg SL, Miller GE, Brehm JM, Celedón JC. Stress and asthma: novel insights on genetic, epigenetic, and immunologic mechanisms. J Allergy Clin Immunol. 2014;134(5):1009-15.
17. Dahl R, Lundback B, Malo JL, Mazza JA, Nieminen MM, Saarelainen P, et al. A dose-ranging study of fluticasone propionate in adult patients with moderate asthma. Chest. 1993;104(5):1352-8.
18. O'byrne PM, Barnes PJ, Rodriguez-Roisin R, Runnerstrom E, Sandstrom T, Svensson K, et al. Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med. 2001;164(8):1392-7.
19. Pauwels RA, Löfdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med. 1997;337(20):1405-11.
20. Busse WW, Chervinsky P, Condemi J, Lumry WR, Petty TL, Rennard S, et al. Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma. J Allergy Clin Immunol. 1998;101(4):457-63.
21. Raghavan D, Jain R. Increasing awareness of sex differences in airway diseases. Respirology. 2016;21(3):449-59.
22. Johnston NW, Mandhane PJ, Dai J, Duncan JM, Greene JM, Lambert K, et al. Attenuation of the September epidemic of asthma exacerbations in children: a randomized, controlled trial of montelukast added to usual therapy. Pediatrics 2007;120(3):e702-12.